Studies of bioactivity, conformation and pharmacokinetic profiles of site-specific PEGylated thymosin alpha 1 derivatives.
Qie. Jiankun J; Ma. Jinbo J; Wang. Liangyou L; Xu. Xiaoyu X; Zheng. Jianquan J; Dong. Sijian S; Xie. Jianwei J; Sun. Huixian H; Zhou. Wenxia W; Qi. Chunhui C; Zhao. Xiunan X; Zhang. Yongxiang Y; Liu. Keliang K
Key Findings
- PEG attachment site strongly influences peptide conformation and pharmacokinetics
- The order of impact on PK is alpha‑helix > beta‑turn > random coil > terminal regions
- Immunoactivity of thymosin‑alpha‑1 remains largely unchanged after PEGylation
Practical Outcomes
- If a PEG‑modified thymosin‑alpha‑1 product becomes available, it could offer a longer half‑life while keeping its immune benefits, making dosing potentially less frequent. However, the advantage depends on the exact PEG attachment site, and this chemistry isn’t something DIY‑ers can replicate today.
Summary
Scientists attached a single PEG molecule to different parts of the peptide thymosin‑alpha‑1 and found that where the PEG is placed changes the peptide’s shape and how long it stays in the body, but it doesn’t really affect its immune‑boosting activity.
Abstract
Site-specific mono-PEGylations were performed in different conformational regions of Thymosin alpha 1 (T alpha 1) by introducing one cysteine residue into the chosen site and coupling with thiol-specific mPEG-MAL reagent. Results demonstrated that PEGylated sites and regions influenced the conformations and pharmacokinetic profiles of the peptide greatly with following order: alpha-helix, beta-turn, random coil and terminals, but little on the immunoactivity.
Study Information
pubmed
2007
2007-07-31T00:00:00.000Z
10.2174/187231207781369780
2